Recently launched European investment vehicle AurorA Science has placed its first marker on a company going after one of life sciences’ most infamous oncogene targets: MYC. AurorA Science led Barcelona-based Peptomyc S.L.’s €11.4 million ($13.8 million)...

Megaround for gene therapy play NeurogeneNeurogene Inc. raised $115 million in a series B round led by EcoR1 Capital, with participation by existing investors Redmile Group, Samsara BioCapital and Cormorant Asset Management. New investors include...

The year has been a big one for mRNA, with the modality proving its worth in COVID-19 development, offering both the fastest path to an authorized vaccine and, so far, the strongest efficacy. At least...

As it prepares to deploy two new funds, Westlake Village BioPartners believes the combination of its capital, its connections and a collaboration with a real estate investor will allow a biotech hub to...

Vida leads Locanabio’s $100M B roundLocanabio Inc. raised $100 million in a series B financing led by Vida Ventures, with participation from new investors RA Capital, Invus, Acuta Capital and SVB Leerink as well as existing...

Increased deal flow across the board has led Forbion to split its funds between early and late-stage opportunities, with its latest €460 million ($557.7 million) fund, which closed this week, focused...

Encountering unanticipated investor interest after closing its series A round,  RayzeBio followed up two months later with a series B raise that triples its reserves and frees the platform company from the need to make...

As 2020’s record-setting run of biotech IPOs nears its end, Canadian mAb developer AbCellera rode enthusiasm for its COVID-19 treatment to one of the year’s biggest offerings, then nearly tripled its value in the early...

After getting off to a slow start due to COVID-19 lockdowns, China’s biotechs rallied to raise more money in 2020 than in 2018 and 2019 combined. The bulk of that additional money came from public...

CBC portfolio company Nuance closes $181M series DNuance Biotech raised $181 million in a series D round led by RTW Investments and GT Fund with participation by existing investors CBC Group, Matrix Partners China and...

Three more biotechs gained value in the aftermarket Friday after pricing upsized IPOs, with proteomics company Seer scoring a triple-digit gain while Silverback and Sigilon each rose by double digits. With the trio’s listings, more...

OTV closes $170M fundIsrael-based digital health VC OTV has changed its name from Olive Tree Ventures and closed a $170 million fund. The firm also said it hired Jose Antonio Urrutia Rivas, who was an associate...

Two years after its launch, precision oncology company Kinnate has become at least the twenty-second preclinical biotech to go public on NASDAQ this year, building upon a record the 2020 IPO class broke...

Merck sold its shares in Moderna at a price at least three times their value at the beginning of 2020, although the biotech’s value has continued to rise since the divestiture’s completion as its COVID-19...

AI company Genesis raises $52M series AStanford University spinout Genesis Therapeutics Inc. raised $52 million in a series A round led by Rock Springs Capital; T. Rowe Price Associates, Andreessen Horowitz, Menlo Ventures, Radical Ventures,...